

LOXAPINE inhalation powder (Adasuve®▼)

G
R
E
Y

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of LOXAPINE inhalation powder (Adasuve®▼) for mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder

Loxapine is a psycholeptic agent with high affinity antagonism of dopamine D2 receptors and serotonin 5-HT_{2A} receptors. It binds with noradrenergic, histaminergic, and cholinergic receptors, and its interaction with these systems may influence the spectrum of its pharmacological effects. It is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder and should only be given in a hospital setting.¹

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, clinicians should continue to follow routine clinical practice for the treatment of agitation in patients with schizophrenia or bipolar disorder, and the recommendations made in NICE CG178: [Psychosis and schizophrenia in adults: prevention and management](#) (last updated March 2014).

References

1. Galen Limited. Summary of Product Characteristics; Adasuve 9.1 mg inhalation powder pre-dispensed, 08 February 2018. Accessed 18 June 2018 at: <https://www.medicines.org.uk/emc/product/7332>

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.